Home » Stocks » FHTX

Foghorn Therapeutics, Inc. (FHTX)

Stock Price: $15.54 USD -0.46 (-2.88%)
Updated Oct 30, 2020 1:28 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 554.70M
Revenue (ttm) n/a
Net Income (ttm) -58.06M
Shares Out 35.34M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $15.54
Previous Close $16.00
Change ($) -0.46
Change (%) -2.88%
Day's Open 16.45
Day's Range 15.20 - 16.45
Day's Volume 122,313
52-Week Range 14.03 - 20.30

More Stats

Market Cap 554.70M
Enterprise Value 581.56M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 35.34M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.64
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 33.90
Revenue n/a
Operating Income n/a
Net Income -58.06M
Free Cash Flow n/a
Net Cash -26.87M
Net Cash / Share -0.75
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-51.08-26.05
Net Income-51.13-26.34
Shares Outstanding4.192.95
Earnings Per Share-12.20-8.94
Operating Cash Flow-46.34-22.65
Capital Expenditures-0.96-1.54
Free Cash Flow-47.30-24.19
Cash & Equivalents17.2640.59
Total Debt16.637.03
Net Cash / Debt0.6333.56
Book Value-88.02-39.27
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Foghorn Therapeutics, Inc.
Country United States
Employees 85
CEO Adrian Gottschalk

Stock Information

Ticker Symbol FHTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FHTX
IPO Date October 23, 2020


Foghorn Therapeutics, a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.